{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:30:50Z","timestamp":1770903050356,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18829-x","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:19:19Z","timestamp":1764775159000},"page":"2591-2592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflections: Global Perspectives on Index Lymph Node Surgery after Neoadjuvant Therapy for Stage III Melanoma"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0734-8309","authenticated-orcid":false,"given":"Elan","family":"Novis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervi","family":"Rautalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"18829_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323.","journal-title":"N Engl J Med."},{"key":"18829_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178\u201388.","journal-title":"Nat Med."},{"key":"18829_CR3","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1245\/s10434-021-11236-y","volume":"29","author":"ACJ van Akkooi","year":"2022","unstructured":"van Akkooi ACJ, Hieken TJ, Burton EM, et al. Neoadjuvant systemic therapy in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium. Ann Surg Oncol. 2022;29:3694\u2013708.","journal-title":"Ann Surg Oncol."},{"key":"18829_CR4","doi-asserted-by":"publisher","unstructured":"Novis E, Rautalin M, Amaria RN, et al. International survey on evidence for index lymph node surgery after neoadjuvant systemic therapy for stage III melanoma. Ann Surg Oncol. 2025. (https:\/\/doi.org\/10.1245\/s10434-025-18475-3).","DOI":"10.1245\/s10434-025-18475-3"},{"issue":"18","key":"18829_CR5","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391(18):1696\u2013708.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18829-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:51Z","timestamp":1770899991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18829-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18829"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18829-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alexander Christopher Jonathan van Akkooi holds honoraria or a consultancy or advisory role in Adium, Amgen, Bristol-Myers Squibb, Daiichi Sankyo, Genmab, Menarini Silicon Biosystems, Merck Serono-Pfizer, MSD Merck, Neracare, Novartis, Pierre Fabre, Provectus, Regeneron, Replimune, Sanofi, Sirius Medical, SkylineDx, and 4SC; research funding from Amgen, Merck Serono-Pfizer, and SkylineDx; and NHMRC Clinical Trials and Cohort Studies grant number 2043780.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}